BioGaia AB (publ)
BIOGY
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.5B
Close$
$9.59
22.9% downside
Current Fair Value
22.9% downsideOvervalued by 22.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.50 Billion |
|---|---|
| Enterprise Value | $11.06 Billion |
| Dividend Yield | $0.42 (3.42%) |
| Earnings per Share | $3.29 |
| Beta | 0.32 |
| Outstanding Shares | 101,162,000 |
Return
| Return on Equity | 31.45% |
|---|---|
| Return on Assets | 25.91% |
| Return on Invested Capital | 39.93% |
Valuation & Multiples
| P/E Ratio | 34.05 |
|---|---|
| PEG | 196.26 |
| Price to Sales | 0.83 |
| Price to Book Ratio | 1.25 |
| Enterprise Value to Revenue | 7.02 |
| Enterprise Value to EBIT | 24.63 |
| Enterprise Value to Net Income | 31 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 17, 2026
EPS Estimate
$1.05
Average shareholder expectationRevenue Estimate
$438.25 M
Average shareholder expectationNext Earnings Call
Expected Date
October 22, 2026
EPS Estimate
$0.90
Average shareholder expectationRevenue Estimate
$383.54 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioGaia AB (publ)
251 employees
CEO: Theresa Agnew BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantag...